Are the Antagonists of the Renin–Angiotensin System Also Anticancer Agents?

Review Article


The antagonists of the renin–angiotensin system (RAS) have gained increasing popularity in the last two decades due to their indisputable efficacy in a number of cardiovascular disorders, coupled with an unsurpassed tolerability. However some years ago a partial and non-predefined meta-analysis raised the possibility that angiotensin receptor antagonists in particular may increase the incidence of cancer. This observation, although not confirmed by subsequent, larger analyses, caused a remarkable and understandable concern even outside the medical community. Herein we will summarize the available evidence pro and con the hypothesis of a carcinogenetic activity of RAS antagonists coming to the conclusion that these drugs may actually exert an anticancer action.


Renin-angiotensin system Renin-angiotensin system antagonists Cancer 


  1. 1.
    Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Publ Health. 2011;32:5–22.CrossRefGoogle Scholar
  2. 2.
    Hunter DJ, Srinath Reddy K. Noncommunicable diseases. N Engl J Med. 2013;369:1336–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20:72–80.PubMedCrossRefGoogle Scholar
  4. 4.
    The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;2013(31):1281–357.Google Scholar
  5. 5.
    Volpe M, Azizi M, Danser AH, Nguyen G, Ruilope LM. Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur Heart J. 2011;32:19–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer; meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627–36.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and the risk of cancer: network meta-analyses and trial sequential analyses of 324168 participants from randomised trials. Lancet Oncol. 2011;12:65–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Ager EI, Neo J, Cristophi C. The renin–angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Doi C, Egashira N, Kawabata A, Maurya DK, Ohta N, Uppalapati D, et al. Angiotensin II type 2 receptor signalling significantly attenuates growth of murine pancreatic carcinoma grafts in syngenic mice. BMC Cancer. 2010;10:67.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Pickel L, Matsuzuka T, Doi C, Ayuzawa R, Maurya DK, Xie SX, et al. Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther. 2010;9:277–85.Google Scholar
  12. 12.
    Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammatory related pathways. Lab Invest. 2002;82:747–56.PubMedCrossRefGoogle Scholar
  13. 13.
    Silvestre JS, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, et al. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 2002;90:1072–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension. 2004;43:276–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Moltzer E, Verkuil AV, van Veghel R, Danser AH, van Esch JH. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin type 2 receptor-mediated vasodilation. Hypertension. 2010;55:516–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Machado RD, Santos RA, Andrade SP. Mechanisms of angiotensin (1–7) induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2001;280:R994–1000.PubMedGoogle Scholar
  17. 17.
    Menon J, Soto-Pantoja DR, Callahan, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1–7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007;67:2809–15.Google Scholar
  18. 18.
    Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, et al. Requirement of prorenin receptor and vacuolar H + ATPase-mediated acidification for Wnt signalling. Science. 2010;327:459–63.PubMedCrossRefGoogle Scholar
  19. 19.
    The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138769 individuals. J Hypertens. 2011;29:623–35.Google Scholar
  20. 20.
    Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Rao GA, Mann JR, Shoaibi A, Pai SG, Bottai M, Sutton SS, et al. Angiotensin receptor blockers: are they related to lung cancer? J Hypertens. 2013;31:1669–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135:1429–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. BJC. 2010;103:1644–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Kim ST, Park KH, Oh SC, et al. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 2012;83:354–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23:221–30.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Division of Internal Medicine and Hypertension Center, Department of Clinical Sciences and Community Health, San Giuseppe HospitalUniversity of MilanMilanItaly
  2. 2.Department of Internal MedicineOspedale San GiuseppeMilanItaly

Personalised recommendations